ArticleFrontiers in immunology2026
Immunopathological signatures in congenital tuberculosis-a case-matched study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Congenital tuberculosis (CTB) is a rare and life-threatening condition with a mortality rate of approximately 53% even with clinical intervention, which is markedly higher than that of adult tuberculosis (ATB). To date, the phenotypic and functional characteristics of immune cells in CTB neonates remain largely uncharacterized. Methods: In this case-control study, we enrolled nine CTB neonates and nine paired healthy control (pHC) neonates, collecting basic clinical characteristics of the infants and their mothers, and comparing routine blood test results, C-reactive protein (CRP) levels, and lymphocyte subset profiles via flow cytometry during hospitalization. For exploratory mechanistic investigation, we performed single-cell RNA sequencing (scRNA-seq) on peripheral blood mononuclear cells isolated from one pHC neonate and one CTB neonate at the pre-symptomatic early stage, with additional scRNA-seq data of one ATB patient included for comparative analysis. Results: At the clinical level, CTB neonates exhibited gradual lymphocyte depletion, reduced regulatory T (Treg) cell frequency, and an excessive innate immune response-changes that may drive an overwhelming pro-inflammatory response alongside a compromised adaptive immune response. Exploratory scRNA-seq analysis of the single CTB and pHC neonate revealed a general suppression of immune function in T and natural killer (NK) cells in CTB. T cell subset transcriptomic profiling further showed decreased proportions of Tregs, Th1/17 cells, proliferating T cells, and cytotoxic CD8+ T cells in the CTB neonate, with a concomitant reduction in cytotoxic NK cell frequency. The proportion of myeloid cell subsets in CTB was similar to that in HCs, however, myeloid cells in CTB showed a generally activated inflammatory response. Compared with ATB, myeloid cells of CTB expressed high levels of inflammatory markers. Transcriptomic features of T and NK cell function in the CTB neonate were similar to those in the ATB patient, yet these immune cells in the CTB neonate showed a generally weaker antigen presentation capacity. These preliminary features may partially underpin the high mortality of CTB. Discussion: Notably, the scRNA-seq findings presented here are exploratory and hypothesis-generating, and should be interpreted with caution. Further studies with expanded scRNA-seq cohorts are urgently needed to validate these initial observations and elucidate the core immune pathophysiological mechanisms of CTB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.